+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment with interferon-alpha (IFNalpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNalpha-induced depressive and anxiety symptoms and immune activation



Treatment with interferon-alpha (IFNalpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFNalpha-induced depressive and anxiety symptoms and immune activation



Molecular Psychiatry 6(4): 475-480



We have shown that treatment with interleukin-2 (IL-2) or interferon-alpha (IFNalpha) may induce depressive symptoms and activation of the cytokine network and that IL-2 treatment may diminish serum dipeptidyl pepdidase IV (DPP IV) activity. DPP IV (EC 3.4.14.5) is a membrane bound serine protease which catalyzes the cleavage of some cytokines and neuroactive peptides which modulate T cell activity.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 011593702

Download citation: RISBibTeXText


Related references

IFNalpha-2b and ribavirin combined therapy in naive patients with HCV type 1 chronic hepatitis The role of an IFNalpha-2b induction treatment. Hepatology 36(4 Part 2): 590A, 2002

Impact of sustained viral response after IFNalpha-2b+ribavirin combination therapy or IFNalpha-2b monotherapy on health-related quality of life in Japanese patients with chronic hepatitis C. Hepatology 34(4 Pt 2): 580A, 2001

Efficacy and safety of long term treatment of chronic hepatitis B with IFNalpha plus lamivudine versus IFNalpha alone. Gastroenterology 118(4 Suppl 2 Part 1): AASLD A937, 2000

In vitro effect of amikacin, imipenem, cefodizime, IFNalpha-2a alone and combinations of antibiotics with IFNalpha-2a on polymorphonuclear leukocyte function in chronic hepatitis patients. ChemoTherapy 47(4): 261-265, 2001

Interferon-alpha daily dose versus IFNalpha plus ribavirin for treatment-naive chronic hepatitis C patients infected by genotype 1b. BioDrugs 17(4): 281-286, 2003

Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. European Psychiatry 21(3): 204-210, 2006

Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Research 105(1-2): 45-55, December 15th, 2001

The activation of intracellular tyrosine kinases by interferon-alpha (IFNalpha) correlates with its antiproliferative activity in B-lymphoid cell lines, but not in B-cell chronic lymphocytic leukemia patients. Annals of Hematology 79(3): 119-126, 2000

Natural interferon alpha (Le-IFNalpha) treatment in patients with thrombocytopenia during chronic HCV infection--our observations. Przeglad Epidemiologiczny 63(3): 383-386, 2009

In vitro anti-myeloma activity of IFNalpha/VCAM-Ig; bispecific immunoadhesin for targeting IFNalpha to cells expressing activated VLA-4. Blood 98(11 Part 2): 311b, 2001

Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: An Italian multicentre study of dose and duration of IFNalpha treatment. Research in Virology 149(5): 283-291, 1998

Lower activities of serum peptidases predict higher depressive and anxiety levels following interferon-alpha-based immunotherapy in patients with hepatitis C. Acta Psychiatrica Scandinavica 109(2): 126-131, 2004

Interferon alpha (IFNalpha) treatment for Sjögren's syndrome. Nihon Rinsho. Japanese Journal of Clinical Medicine 64(7): 1345-1353, 2006

Lowered serum dipeptidyl peptidase IV activity is associated with depressive symptoms and cytokine production in cancer patients receiving interleukin-2-based immunotherapy. Neuropsychopharmacology 24(2): 130-140, 2001